Bank of America Corp DE Sells 546,799 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Bank of America Corp DE decreased its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 69.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 245,508 shares of the company's stock after selling 546,799 shares during the quarter. Bank of America Corp DE owned approximately 0.29% of Syndax Pharmaceuticals worth $3,246,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Virtus ETF Advisers LLC lifted its holdings in Syndax Pharmaceuticals by 18.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock worth $70,000 after buying an additional 827 shares during the period. E Fund Management Co. Ltd. increased its stake in shares of Syndax Pharmaceuticals by 14.4% in the fourth quarter. E Fund Management Co. Ltd. now owns 12,603 shares of the company's stock valued at $167,000 after buying an additional 1,583 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Syndax Pharmaceuticals by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,099 shares of the company's stock worth $239,000 after acquiring an additional 1,732 shares during the last quarter. R Squared Ltd acquired a new position in shares of Syndax Pharmaceuticals in the fourth quarter worth approximately $26,000. Finally, Y Intercept Hong Kong Ltd lifted its stake in shares of Syndax Pharmaceuticals by 2.5% in the fourth quarter. Y Intercept Hong Kong Ltd now owns 83,297 shares of the company's stock worth $1,101,000 after acquiring an additional 1,995 shares during the period.

Syndax Pharmaceuticals Stock Performance

Shares of NASDAQ SNDX traded down $0.23 during trading on Wednesday, hitting $10.96. 1,945,108 shares of the company traded hands, compared to its average volume of 1,793,941. The firm has a market capitalization of $943.08 million, a price-to-earnings ratio of -3.02 and a beta of 0.82. The business's fifty day moving average is $11.35 and its 200 day moving average is $13.33. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $8.58 and a fifty-two week high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.98) EPS for the quarter, beating analysts' consensus estimates of ($1.04) by $0.06. The firm had revenue of $20.04 million during the quarter, compared to the consensus estimate of $15.88 million. The business's quarterly revenue was up 1900.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.85) earnings per share. On average, analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Wall Street Zen raised shares of Syndax Pharmaceuticals to a "sell" rating in a research report on Tuesday, May 6th. HC Wainwright reiterated a "buy" rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. Guggenheim restated a "buy" rating and issued a $32.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, May 6th. Citigroup cut their price target on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Finally, Scotiabank lifted their price objective on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a "sector perform" rating in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $35.91.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).